Coloplast A/S - FY 2023/24 Financial Guidance
Coloplast announces financial guidance for the 2023/24 financial year. Organic revenue growth is expected around 8% and the EBIT margin is expected at 27-28%. The assumptions on the financial guidance are laid out below.
Organic growth is expected around 8% in constant currencies. The guidance assumes growth across business areas and regions to be largely in line with the Strive25 ambitions, except for China.
- Chronic Care:
- Improvement in growth in China, however, China is not expected to return to the Strive25 ambitions of double-digit growth, due to continued impact from average value per patient which remains below pre-COVID levels, impacted by consumer sentiment
- Advanced Wound Care is expected to deliver growth above the market
- Interventional Urology is expected to deliver high-single digit growth
- Voice and Respiratory Care is expected to grow at 8-10%
- No current knowledge of significant health care reforms; positive pricing impact is expected. The expectation of long-term price pressure of up to 1% annually is unchanged
- A stable supply and distribution of products across the company
Reported growth in DKK is expected to be around 12% and assumes:
- Contribution from the Kerecis acquisition is expected around 4%-points (11 months impact)
- Limited negative impact from currencies
The reported EBIT margin before special items is expected at 27-28%, and includes the following assumptions:
- Input costs development:
- Raw materials – mid single-digit price increase
- Tailwind from total energy costs of around DKK 100 million on the gross margin
- Tailwind from freight cost
- Wages in Hungary – double-digit increase, similar to 2022/23
- A one-off baseline benefit of around 40 basis points from the Italian pay-back reform provision which was included in the FY 2022/23 gross margin
- Prudent management of operating costs, expected to grow below reported revenue in DKK (excluding acquired growth)
- Incremental investments at the lower end of the Strive25 guidance (up to 2% of sales in incremental OPEX investments)
- Benefit from operational synergies related to integration of Atos Medical on Coloplast infrastructure
- Negative impact from Kerecis of around 100 basis points, which includes around DKK 100 million in PPA amortisation
- Negative impact from currencies of around 50 basis points
Special items are expected to be around DKK 50 million in FY 2023/24, related to the integration of Atos Medical.
Capital expenditures are expected to be around DKK 1.4 billion. The effective tax rate is expected to be around 22%.
The forward-looking statements in this announcement, including revenue and earnings guidance, do not constitute a guarantee of future results and are subject to risk, uncertainty and assumptions, the consequences of which are difficult to predict.
The forward-looking statements are based on our current expectations, estimates and assumptions and are provided on the basis of information available to us at the present time.
Major fluctuations in the exchange rates of key currencies, significant changes in the healthcare sector or major developments in the global economy may impact our ability to achieve the defined long-term targets and meet our guidance. This may impact our company’s financial results.
For further information, please contact
Investors and analysts
Executive Vice President, CFO
Tel. +45 4911 1111
Senior Director, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Kristine Husted Munk
Senior Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 3266
Press and media
Sr. Media Relations Manager
Tel. +45 4911 2623
Company reg. (CVR) no. 69749917
This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.
Coloplast was founded on passion, ambition, and commitment. We were born from a nurse’s wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound and Skin Care, Interventional Urology and Voice and Respiratory Care.
The Coloplast logo is a registered trademark of Coloplast A/S. © 2023-11.
All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iveco Group N.V. publishes its 2024 Corporate Calendar29.11.2023 18:30:00 CET | Press release
Turin, 29th November 2023. Iveco Group N.V. (EXM: IVG) announces the following corporate calendar dates for 2024: DateEarnings releases9th FebruaryResults for 4th quarter and preliminary annual results 202310th MayResults for 1st quarter 202425th JulyResults for 2nd quarter and 1st half 20247th NovemberResults for 3rd quarter 2024 The Annual General Meeting for the approval of Iveco Group N.V.’s Financial Statements at 31st December 2023 is scheduled to take place in mid April 2024 (*). The 2024 corporate calendar is available on the corporate website: www.ivecogroup.com. (*) In compliance with the requirements set forth by the lnstructions of the Regulation of Borsa Italiana S.p.A., please note that, should the Annual General Meeting resolve a dividend related to the 2023 financial year, the month planned for the dividend detachment (ex-date) would be April. This information is provided for the aforesaid regulatory provisions only and it cannot be interpreted in any way as a forecast
PUBLICATION OF A TRANSPARENCY NOTIFICATION29.11.2023 18:30:00 CET | Press release
Publication on November 29, 2023 at 18:30 CET after market closing Regulated information EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) PUBLICATION OF A TRANSPARENCY NOTIFICATION (Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings) On November 27, 2023, EVS Broadcast Equipment has received a transparency notification indicating that Otus Capital Management Limited now holds 4.99% of the voting rights of the company. Otus Capital Management Limited has therefore crossed down the threshold of 5%. The notification, dated November 27, 2023, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotification by: A parent undertaking or a controlling personPersons subject to the notification requirement: Otus Capital Management Limited, 29 Queen Anne’s Gate, London SW1H 9BU, UK; Andrew GibbsTransaction date: November 24, 2023Threshold that
IDEX - Disclosure of large shareholding - 29 Nov 202329.11.2023 18:30:00 CET | Press release
Reference is made to the announcement by IDEX Biometrics ASA on 15 November 2023 regarding a private placement of shares, and the announcement by Sundt AS on 16 November 2023 regarding lending of shares. As a result of the re-delivery of shares, Sundt AS discloses the following information pursuant to Section 4-2 of the Norwegian Securities Trading Act and the Securities Trading Act Regulations: On 29 November 2023, following re-delivery of 45,000,000 shares in IDEX, Sundt AS’s holdings of shares increased from 61,512,922 shares to 106,512,922 which represents 7.6% of the share capital based on 1,396,621,040 shares in issue following the private placement. This notice was published by Erling Svela, Vice president of finance, on 29 November 2023 at 18:30 CET on behalf of IDEX Biometrics ASA.
SMISS launched its electronic vapor gadgets technology platform TempSure™, the world's 1st cannabis vape hardware featuring intelligent duplex communication29.11.2023 18:00:00 CET | Press release
SHENZHEN, China, Nov. 29, 2023 (GLOBE NEWSWIRE) -- As one of the largest exhibitions in the global cannabis industry, the MJBizCon 2023 CBD/THC/Cannabis Expo opened in Las Vegas as scheduled. On November 29th local time, SMISS officially launched the World's 1st Cannabis Vape Hardware Featuring Intelligent Duplex Communication, TempSure™ at the event. The platform utilizes advanced technology to provide users with the best intelligent vaporization experience. The name TempSure™ implies precise vaporization temperature control, offering users the perfect CBD vaporization experience. TempSure™ has developed an intelligent MCU control chip and a proprietary PID dynamic compensation technology solution. By accurately monitoring the heating state of CeramicMesh™ coil vaporization (oil conductivity, oil temperature, and smoke signal), it dynamically adjusts the optimal power energy output to achieve accurate heating temperature control for scientific vaporization. This enables users to exper
Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: publication of a transparency notification29.11.2023 18:00:00 CET | Press release
Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Chère Madame, Cher Monsieur, Veuillez trouver ci-dessous les liens vers le récent communiqué de presse d’Intervest Offices & Warehouses concernant la communication relative à une notification de transparence. Attachments ENG_transparency notification_20231128_FINNL_transparency notification_20231128_FINFR_transparency notification_20231128_FIN